Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

Findings Support Development for Chronic Pain Indications

LA JOLLA, Calif., Feb. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy male and female subjects when dosed once daily for five consecutive days.

"The successful completion of this Phase I trial demonstrating the safety and tolerability of NGX426 when dosed over multiple days provides support for pursuing a Phase II program in chronic indications," said Ev Graham, Chief Executive Officer of TorreyPines. "Combined with the positive results from our recently completed Phase I study of NGX426 in a capsaicin induced pain model, we are very encouraged about the potential for NGX426 to treat both acute and chronic pain conditions."

The Phase I double-blind, placebo-controlled trial enrolled 20 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily oral doses of either 90 mg or 150 mg of NGX426 or placebo for five consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, NGX426 was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.

NGX426, an ester prodrug, is an oral form of tezampanel, TorreyPines most advanced product candidate. Pharmacokinetic analyses from two Phase I studies confirmed that when given to humans, NGX426 is rapidly converted to tezampanel, the active moiety. To date, six Phase II, double-blind, placebo-controlled trials have demonstrated that tezampanel, administered either subcutaneously or intravenously, was more effective than placebo in relieving pain across migraine, nocic
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... ADDISON, TX (PRWEB) November 25, 2014 ... age-defying skincare products, earned three prestigious MarCom Awards for ... , Nerium received a Platinum MarCom Award, the organization’s ... Real Event in St. Louis held in April of ... for more than 14,000 attendees. Additionally, Nerium was awarded ...
(Date:11/26/2014)... 26, 2014 CURE™ magazine ... on December 5, 2014, in San Francisco prior to ... Heroes event will honor clinicians, caregivers, and advocates who ... neoplasms (MPNs). , Special guest speaker Charles Esten, ... cancer journey at the reception. Over a decade ...
(Date:11/26/2014)... Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... testing solutions for the detection of foodborne pathogens, today announced ... Piper Jaffray  26 th Annual Healthcare Conference on December ... at The New York Palace in New York, ... information concerning the Company, its operations, strategies and prospects may ...
(Date:11/24/2014)... , November 24, 2014   ... online on ScienceDirect   Elsevier , a ... services, is pleased to announce the launch of the latest ... Current Opinion in Food Science . ... will provide specialists with a new platform to keep up-to-date ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... Md., Oct. 4, 2011 Northwest Biotherapeutics (OTC.BB: ... be presenting at the second annual Cancer Immunotherapy: ... at the New York Academy of Medicine in ... opinion leaders, industry executives, and other stakeholders to ...
... LAFAYETTE, Ind., Oct. 4, 2011 Kylin Therapeutics, ... that it has received a notice of allowance ... for its second U.S. patent application. This newly ... as well as expanded areas on Kylin,s proprietary ...
... Oct. 4, 2011 Sequenom, Inc. (NASDAQ: ... analysis solutions, today announced the launch of its iPLEX ... associated with drug absorption, distribution, metabolism, and excretion (ADME). ... of pre-designed single nucleotide polymorphisms (SNP), insertions and deletions ...
Cached Biology Technology:NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 2NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 3NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 4Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology 2Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 2Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 3
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/5/2014)... Kelly Redmond has dedicated his career to understanding ... a general audience. , As deputy director and ... at Nevada,s Desert Research Institute, Redmond has more ... application and dissemination of climate data to the ... Meeting in San Francisco on December 15-19, 2014 ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... , This release is available in ... the US and Europe harbour more plant species than ... closer related to each other and often share similar ... environmental impacts than rural ecosystems. This is concluded by ...
... Strasbourg 18/04/12 - Technology has transformed the way humans interact ... big ideas that will drive growth in marine and maritime ... and policy will gather at the 3rd Marine Board Forum ... Marine Board has convened this flagship event on the understanding ...
... Lugano-CH/Aurora-US-CO/Geneva-CH, 18 April 2012 -- New techniques for identifying ... screening, a nanotech ,nose, and a method to examine ... according to presentations at the 3rd European Lung Cancer ... lung cancer is vital to improve lung cancer survival ...
Cached Biology News:Live fast, die young 2New technologies for a blue future 2Early detection techniques offer hope for improved outcomes in lung cancer patients 2Early detection techniques offer hope for improved outcomes in lung cancer patients 3Early detection techniques offer hope for improved outcomes in lung cancer patients 4
Digital display of time, vacuum and temperature , Dual vacuum control of ramping rate and ultimate level , Comes complete with RH40-12 (40 x 1.5 ml) Rotor and (2) Glass Condensation Flasks. ...
...
... The Jouan RC10 series of vacuum ... product protection features allied to rapid and ... modules can be combined with oil-free or ... traps and a wide selection of rotors ...
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
Biology Products: